Zhou Yunzhi, Gao Yongping, Zhang Nan, Li Xiaoli, Wang Hui, Wang Shufang, Liu Jiankun, Gao Hong, Wang Hongwu
Department of Respiratory Medicine, Emergency General Hospital, Beijing, China.
J Thorac Dis. 2021 Feb;13(2):1100-1105. doi: 10.21037/jtd-20-1493.
Primary lung cancer with severe central airway obstruction (CAO) is often life-threatening. In this study, we investigated the clinical efficacy and safety of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection in treatment of malignant central airway obstruction (MCAO) caused by primary squamous cell lung cancer.
We retrospectively analyzed patients with MCAO caused by primary squamous cell lung cancer treated with and without bronchoscopic intratumoral injection of cisplatin plus rh-endostatin between January 2007 and June 2016.
A total of 206 patients received cisplatin plus rh-endostatin intratumoral injection, and 113 without injection. Dyspnea grade, degree of stenosis, quality of life and lung function of all patients were significantly improved at 1 week after treatment compared with baseline. Both groups achieved good airway patency (97.1% . 93.8%, P=0.156). Followed up at 2 months, all parameters were improved in the injection group compared with baseline, while no statistical differences were observed in the non-injection group (P>0.05). The injection group achieved airway patency in 155 (75.2%) of 206 patients, which was significantly superior to the non-injection group [20 (17.7%) of 113, P<0.001]. In addition, the restenosis rate of the injection group was lower compared with the non-injection group (22.5% . 81.1%, P<0.001, respectively). No serious complications were observed in two groups.
Cisplatin plus rh-endostatin intratumoral injection is effective and safe for the therapy of MCAO caused by primary squamous cell lung cancer.
伴有严重中央气道阻塞（CAO）的原发性肺癌通常危及生命。在本研究中，我们调查了顺铂联合重组人内皮抑素（rh-内皮抑素）瘤内注射治疗原发性肺鳞状细胞癌所致恶性中央气道阻塞（MCAO）的临床疗效和安全性。
我们回顾性分析了2007年1月至2016年6月期间接受或未接受支气管镜下瘤内注射顺铂联合rh-内皮抑素治疗的原发性肺鳞状细胞癌所致MCAO患者。
共有206例患者接受了顺铂联合rh-内皮抑素瘤内注射，113例未接受注射。与基线相比，所有患者在治疗后1周时的呼吸困难分级、狭窄程度、生活质量和肺功能均有显著改善。两组均实现了良好的气道通畅（97.1% 对93.8%，P = 0.156）。在2个月时进行随访，注射组的所有参数与基线相比均有所改善，而非注射组未观察到统计学差异（P > 0.05）。注射组206例患者中有155例（75.2%）实现了气道通畅，显著优于非注射组[113例中的20例（17.7%），P < 0.001]。此外，注射组的再狭窄率低于非注射组（分别为22.5% 对81.1%，P < 0.001）。两组均未观察到严重并发症。
顺铂联合rh-内皮抑素瘤内注射治疗原发性肺鳞状细胞癌所致MCAO有效且安全。
